We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$11.5B
1-Year Est. Return
168.77%
This Fund
S&P 500
This Quarter
Est. Return
+15.8%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$5.47B
AUM Growth
+$335M
(+6.5%)
Cap. Flow
+$416M
Cap. Flow
% of AUM
7.6%
Top 10 Holdings %
Top 10 Hldgs %
51.96%
Holding
75
New
18
Increased
7
Reduced
14
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nkarta
NKTX
|
+$165M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$143M |
| 3 |
ITOS
iTeos Therapeutics
ITOS
|
+$119M |
| 4 |
VXRT
Vaxart
VXRT
|
+$96.3M |
| 5 |
Seres Therapeutics
MCRB
|
+$79M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novavax
NVAX
|
+$434M |
| 2 |
TG Therapeutics
TGTX
|
+$91.2M |
| 3 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$84.2M |
| 4 |
Stoke Therapeutics
STOK
|
+$26.7M |
| 5 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$25.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.86% |
| 2 | Miscellaneous | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Keros Therapeutics
KROS
$221M
| $72.3M | 1.32% |
1,875,000
| – | – |
|
|
VXRT
27
DELISTED
Vaxart
VXRT
| $71.9M | 1.32% |
+10,810,937
| New | +$96.3M |
|
28
Wave Life Sciences
WVE
$879M
| $66M | 1.21% |
7,775,207
| – | – |
|
29
PMV Pharmaceuticals
PMVP
$72.7M
| $60.7M | 1.11% |
+1,710,265
| New | +$62.9M |
|
30
Dyne Therapeutics
DYN
$3.34B
| $56.6M | 1.04% |
+2,805,045
| New | +$61.6M |
|
|
INZY
31
DELISTED
Inozyme Pharma
INZY
| $52.7M | 0.96% |
+2,003,653
| New | +$49.8M |
|
32
Geron
GERN
$842M
| $52.4M | 0.96% |
30,126,299
| – | – |
|
|
AKUS
33
DELISTED
Akouos Inc
AKUS
| $52.2M | 0.95% |
2,281,249
| – | – |
|
|
ORTX
34
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $50.6M | 0.93% |
1,231,521
+191,202
| +18% | +$9.88M |
|
35
Cardiff Oncology
CRDF
$104M
| $46.7M | 0.85% |
+3,290,000
| New | +$21.7M |
|
36
Relay Therapeutics
RLAY
$4.16B
| $42.6M | 0.78% |
+1,000,000
| New | +$38.1M |
|
|
INBX
37
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $38.3M | 0.7% |
+2,129,003
| New | +$38.6M |
|
38
Alector
ALEC
$228M
| $38.1M | 0.7% |
3,618,748
-508,600
| -12% | -$8.23M |
|
|
CRNX
39
DELISTED
Crinetics Pharmaceuticals
CRNX
| $36.5M | 0.67% |
2,328,698
| – | – |
|
40
Arcutis Biotherapeutics
ARQT
$2.96B
| $34.1M | 0.62% |
1,165,184
| – | – |
|
41
Ardelyx
ARDX
$878M
| $32.9M | 0.6% |
6,260,904
| – | – |
|
|
VRNA
42
DELISTED
Verona Pharma
VRNA
| $31.8M | 0.58% |
+5,100,000
| New | +$35.2M |
|
43
Relmada Therapeutics
RLMD
$474M
| $29.4M | 0.54% |
781,290
-70,617
| -8% | -$2.73M |
|
|
SCPH
44
DELISTED
scPharmaceuticals
SCPH
| $26.2M | 0.48% |
3,518,998
| – | – |
|
|
IMGN
45
DELISTED
Immunogen Inc
IMGN
| $25.3M | 0.46% |
+7,040,485
| New | +$28.4M |
|
46
Larimar Therapeutics
LRMR
$406M
| $23M | 0.42% |
1,515,151
| – | – |
|
47
Sutro Biopharma
STRO
$275M
| $21.3M | 0.39% |
211,821
+19,857
| +10% | +$1.88M |
|
48
Ocular Therapeutix
OCUL
$2.24B
| $20.8M | 0.38% |
2,727,272
| – | – |
|
|
PAND
49
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
| $20.3M | 0.37% |
+1,770,023
| New | +$30.3M |
|
|
PRVL
50
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $19.5M | 0.36% |
1,915,568
-579,123
| -23% | -$7.77M |
|
Similar funds
AAIS
MG
CC
AI
BMSSC
HTC
WAM
RA Capital Management's Q3 2020 Portfolio in Review
As of Q3 2020, RA Capital Management held 75 positions worth $5.47B, up 6.5% from $5.13B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
RA Capital Management deployed $416M of net new capital in Q3 2020, opening 18 new positions and adding to 7 existing holdings. Its largest new stake was Nkarta: 5,605,129 shares worth $168M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Novavax, an estimated $434M trimmed.
- RA Capital Management's largest Q3 2020 buy was Nkarta: 5,605,129 shares worth $168M.
- RA Capital Management added most to Ascendis Pharma A/S in Q3 2020, an estimated $143M increase.
- RA Capital Management's biggest Q3 2020 reduction was Novavax, cutting an estimated $434M.
- RA Capital Management fully exited Momenta Pharmaceuticals, Inc. in Q3 2020, selling an estimated $84.2M.
- RA Capital Management's ten largest holdings make up 52% of its $5.47B portfolio in Q3 2020.
- RA Capital Management opened 18 new positions and closed 5 in Q3 2020.
- RA Capital Management's portfolio value rose 6.5% quarter-over-quarter to $5.47B.
Based on RA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.